Hualan Biological Vaccine Inc. (SHE:301207)

Hualan Biological Vaccine Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	974.6	1,126	2,409	1,824	1,830	2,425
Other Revenue	1.83	1.83	1.2	1.57	-	1.28
Revenue	976.44	1,128	2,410	1,826	1,830	2,426
Revenue Growth (YoY)	-40.80%	-53.21%	32.03%	-0.23%	-24.59%	131.30%
Cost of Revenue	290.83	286.78	382.02	369.19	354.01	288.64
Gross Profit	685.6	841.03	2,028	1,456	1,476	2,138
Selling, General & Admin	541.68	582.54	1,019	776.35	647.5	915.27
Research & Development	193.91	162.64	91.11	134.64	144.13	110.94
Other Operating Expenses	18.34	10.61	15.18	12.59	10.84	13.25
Operating Expenses	765.11	746.39	1,146	952.36	803.51	1,083
Operating Income	-79.51	94.64	881.98	504.09	672.29	1,055
Interest Expense	-4.25	-6.1	-6.08	-10.69	-13.32	-2
Interest & Investment Income	80.5	89.29	81.93	72.01	28.82	9.4
Currency Exchange Gain (Loss)	0.06	0.06	-0.23	-0.11	0.25	0.23
Other Non Operating Income (Expenses)	-0.15	-0.08	-0.15	0.08	-0.19	-0.23
EBT Excluding Unusual Items	-3.35	177.81	957.44	565.37	687.85	1,062
Gain (Loss) on Sale of Investments	20.39	24.3	39.68	16.85	14.25	1.86
Gain (Loss) on Sale of Assets	-0.03	-0.14	-0.2	0.63	-	-
Asset Writedown	12.04	-0.24	-0.25	-0.05	-1	-0.33
Other Unusual Items	17.23	12.82	10.21	6.68	4.65	10.36
Pretax Income	46.27	214.55	1,007	589.48	705.75	1,074
Income Tax Expense	-24.19	9.03	146.91	69.84	84.78	149.14
Net Income	70.46	205.52	859.97	519.63	620.97	924.91
Net Income to Common	70.46	205.52	859.97	519.63	620.97	924.91
Net Income Growth	-85.84%	-76.10%	65.50%	-16.32%	-32.86%	146.45%
Shares Outstanding (Basic)	595	598	601	590	540	540
Shares Outstanding (Diluted)	595	598	602	590	540	540
Shares Change (YoY)	-1.11%	-0.71%	2.03%	9.33%	0.01%	-0.24%
EPS (Basic)	0.12	0.34	1.43	0.88	1.15	1.71
EPS (Diluted)	0.12	0.34	1.43	0.88	1.15	1.71
EPS Growth	-85.68%	-75.93%	62.20%	-23.46%	-32.86%	147.05%
Free Cash Flow	282.04	416.45	825.42	196.01	-66.73	161.43
Free Cash Flow Per Share	0.47	0.70	1.37	0.33	-0.12	0.30
Dividend Per Share	0.800	0.200	0.600	0.200	0.133	-
Dividend Growth	33.33%	-66.67%	200.00%	50.04%	-	-
Gross Margin	70.22%	74.57%	84.15%	79.78%	80.65%	88.10%
Operating Margin	-8.14%	8.39%	36.59%	27.61%	36.74%	43.47%
Profit Margin	7.22%	18.22%	35.68%	28.46%	33.94%	38.12%
Free Cash Flow Margin	28.88%	36.93%	34.24%	10.74%	-3.65%	6.65%
EBITDA	60.89	235	1,022	638.51	740.2	1,096
EBITDA Margin	6.24%	20.84%	42.41%	34.98%	40.45%	45.16%
D&A For EBITDA	140.4	140.37	140.33	134.42	67.91	40.85
EBIT	-79.51	94.64	881.98	504.09	672.29	1,055
EBIT Margin	-8.14%	8.39%	36.59%	27.61%	36.74%	43.47%
Effective Tax Rate	-	4.21%	14.59%	11.85%	12.01%	13.89%
Revenue as Reported	976.44	1,128	2,410	1,826	1,830	2,426

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.